Oritavancin - Glycopeptide Antibiotic for Multidrug-Resistant Gram-Positive Pathogens

Print

Oritavancin has a number of properties that may confer benefits in the treatment of serious gram-positive infections if it receives regulatory approval.
 
«Back

Return to Profile




Home
New On This Site
Products & Services
Company A-Z
Industry Projects
White Papers
Jobs & Careers
Press Releases
Events & Exhibitions
Newsletter
Advertise With Us
About Us
Client Area

For every phase of your drug development